Literature DB >> 12203855

Early infection and progression of cystic fibrosis lung disease.

Christian Koch1.   

Abstract

Chronic Pseudomonas aeruginosa infection is the major limitation in overall survival of patients with cystic fibrosis, and elective bronchoscopy shows that infection with this organism starts at a very early age. Early infection with nonmucoid P. aeruginosa gradually develops into chronic infection, characterized by the presence of microcolonies of alginate-producing (mucoid) P. aeruginosa in the bronchial tree. Chronic infection cannot be cured, but aggressive antimicrobial treatment will prolong life expectancy and decrease morbidity. It has, however, over the last decade become evident that early antimicrobial treatment of the initial infection with nonmucoid strains can prevent or at least postpone transition into chronic (mucoid) infection. This treatment strategy is likely to dramatically improve the prognosis of patients with cystic fibrosis in the immediate future. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12203855     DOI: 10.1002/ppul.10135

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  33 in total

Review 1.  Quorum-sensing blockade as a strategy for enhancing host defences against bacterial pathogens.

Authors:  Thomas Bjarnsholt; Michael Givskov
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2007-07-29       Impact factor: 6.237

Review 2.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 3.  Virulence attenuating combination therapy: a potential multi-target synergy approach to treat Pseudomonas aeruginosa infections in cystic fibrosis patients.

Authors:  Elana Shaw; William M Wuest
Journal:  RSC Med Chem       Date:  2020-02-19

Review 4.  Management of the upper airway in cystic fibrosis.

Authors:  Elisa A Illing; Bradford A Woodworth
Journal:  Curr Opin Pulm Med       Date:  2014-11       Impact factor: 3.155

5.  Pseudomonas aeruginosa phenotypes associated with eradication failure in children with cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Bonnie W Ramsey; Hemantha D Kulasekara; Daniel J Wolter; Laura S Houston; Christopher E Pope; Bridget R Kulasekara; Catherine R Armbruster; Jane L Burns; George Retsch-Bogart; Margaret Rosenfeld; Ronald L Gibson; Samuel I Miller; Umer Khan; Lucas R Hoffman
Journal:  Clin Infect Dis       Date:  2014-05-26       Impact factor: 9.079

6.  Neurotrophic and neuroimmune responses to early-life Pseudomonas aeruginosa infection in rat lungs.

Authors:  Silvia Cardenas; Mario Scuri; Lennie Samsell; Barbara Ducatman; Pablo Bejarano; Alexander Auais; Melissa Doud; Kalai Mathee; Giovanni Piedimonte
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-06-11       Impact factor: 5.464

Review 7.  New insights into the pathogenesis of cystic fibrosis sinusitis.

Authors:  Eugene H Chang
Journal:  Int Forum Allergy Rhinol       Date:  2013-11-26       Impact factor: 3.858

8.  Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.

Authors:  Azizah Asgarali; Keith A Stubbs; Antonio Oliver; David J Vocadlo; Brian L Mark
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

9.  Association between mucoid Pseudomonas infection and bronchiectasis in children with cystic fibrosis.

Authors:  Philip M Farrell; Jannette Collins; Lynn S Broderick; Michael J Rock; Zhanhai Li; Michael R Kosorok; Anita Laxova; William M Gershan; Alan S Brody
Journal:  Radiology       Date:  2009-08       Impact factor: 11.105

10.  PCR-based assay for differentiation of Pseudomonas aeruginosa from other Pseudomonas species recovered from cystic fibrosis patients.

Authors:  Theodore Spilker; Tom Coenye; Peter Vandamme; John J LiPuma
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.